Golf Stud… There are several outlying catalysts. If any of them materialize we all will see happy days. Having said that, what is haunting Amarin is the lack of real revenue growth. The rest of the world needs to bear fruit. Additionally, in my view the US is not dead. I believe big pharma can effectively leverage their reputation and Vascepa’s indication to generate additional US sales. I say this simply because we sit right now at 55-60% of Vascepa (molecule) sales. Most other drugs that have gone generic have barely 5-10% of their original sales. There something to be said about this.